TEVA Files 8-K on Operations & Financial Condition
Ticker: TEVJF · Form: 8-K · Filed: Jan 31, 2024 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Teva just dropped an 8-K about its financials, get ready for potential stock moves.**
AI Summary
TEVA PHARMACEUTICAL INDUSTRIES LTD filed an 8-K on January 31, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that Teva is providing an update on its financial performance, likely ahead of a full earnings report. For investors, this matters because it offers an early glimpse into the company's financial health, which could influence stock price movements and future investment decisions.
Why It Matters
This filing signals that Teva is disclosing important financial updates, which can impact investor confidence and the company's stock valuation.
Risk Assessment
Risk Level: medium — While an 8-K itself isn't inherently risky, the 'Results of Operations and Financial Condition' could contain positive or negative news, creating uncertainty.
Analyst Insight
A smart investor would monitor TEVA's news releases closely for the actual financial results mentioned in this 8-K, as this filing only indicates an update is coming, not the details themselves.
Key Numbers
- 001-16174 — SEC File Number (identifies Teva's registration with the SEC)
- 20240131 — Conformed Period of Report (indicates the period covered by the report)
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of earliest event reported and filing date
- New York Stock Exchange (company) — exchange where Teva's American Depositary Shares are registered
- 001-16174 (dollar_amount) — Commission File Number
Forward-Looking Statements
- TEVA will release a more detailed earnings report or press release shortly after this 8-K, providing specific financial figures. (TEVA PHARMACEUTICAL INDUSTRIES LTD) — high confidence, target: 2024-02-15
- The stock price of TEVA will experience volatility as investors react to the undisclosed 'Results of Operations and Financial Condition'. (TEVA) — medium confidence, target: 2024-02-01
FAQ
What specific items are being reported in this 8-K filing by TEVA PHARMACEUTICAL INDUSTRIES LTD?
TEVA PHARMACEUTICAL INDUSTRIES LTD is reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as per the ITEM INFORMATION section of the filing.
What is the filing date and the date of the earliest event reported for this 8-K?
Both the filing date and the date of the earliest event reported for this 8-K is January 31, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
Where are TEVA PHARMACEUTICAL INDUSTRIES LTD's American Depositary Shares traded?
TEVA PHARMACEUTICAL INDUSTRIES LTD's American Depositary Shares, each representing one Ordinary Share, are traded on the New York Stock Exchange under the trading symbol 'TEVA'.
What is the business address of TEVA PHARMACEUTICAL INDUSTRIES LTD as listed in the filing?
The business address of TEVA PHARMACEUTICAL INDUSTRIES LTD is 124 Dvora Hanevi’a Street, Tel Aviv 6944020, Israel, with a telephone number of +972-3-914-8213.
What is the Central Index Key (CIK) for TEVA PHARMACEUTICAL INDUSTRIES LTD?
The Central Index Key (CIK) for TEVA PHARMACEUTICAL INDUSTRIES LTD is 0000818686, as listed in the COMPANY DATA section of the filing.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 13.2 · Accepted 2024-01-31 07:00:30
Filing Documents
- a53889897.htm (8-K) — 27KB
- a53889897ex99_1.htm (EX-99.1) — 1038KB
- 0001157523-24-000137.txt ( ) — 1260KB
- teva-20240131.xsd (EX-101.SCH) — 4KB
- teva-20240131_lab.xml (EX-101.LAB) — 22KB
- teva-20240131_pre.xml (EX-101.PRE) — 16KB
- a53889897_htm.xml (XML) — 4KB
02
ITEM 2.02 Results of Operations and Financial Condition On January 31, 2024, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference. The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description of Document 99.1 Teva Reports 2023 Full Year and Fourth Quarter Financial Results
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: January 31, 2024 By: /s/ Eli Kalif Name: Eli Kalif Title: Executive Vice President, Chief Financial Officer